Under the auspices of

EFLM-IFCC-FIFBCML

BEST PUBLISHED PAPER BY A TRAINEE AWARD

Apply now and take the chance to win:

  • An Oral Communication during the RBSLM Annual Meeting
  • Participate to the EuroMedLab 2027 totally free of charge (registration, transportation & accommodation (up to for 900 €)

Requirements:

  • Be a trainee practicing in Belgium
  • Be a member of the RBSLM
  • Complete your traineeship after September 30, 2026
  • Paper should have been published between August 2025 and October 2026
  • Article in press are welcome
  • Paper cannot be part of a PhD thesis to avoid competition with PhD training

Application procedure:

To apply to the prize, applicant need to fill in the online form, where it will be asked to:

  • Provide the PDF of the published article
  • A short brief in which they describe where and when the work was prepared, who was guiding the work and when the paper was accepted for publication
  • A proof of acceptance in case of a press article

Application Deadline: September 24, 2026 - 23:59

Notification of selected papers will be sent around October 15, 2026

Application Form

Best Abstract Awards

  • BEST ABSTRACT IN CLINICAL CHEMISTRY
  • BEST ABSTRACT IN HEMATOLOGY

Apply now and take the chance to:

  • Give an Oral Communication during the RBSLM Annual Meeting
  • Receive nice gifts

Requirements:

Application procedure:

  • Submit an abstract related to Clinical Chemistry, Hematology or Immunology through the official website before September 24, 2026.
  • Define in which category the abstract is submitted, knowing that serology is in Others and auto-immunity is in Clinical Chemistry

Application Deadline: September 24, 2026 - 23:59

The selected abstracts and winners will be notified around October 15, 2026

SUBMIT YOUR ABSTRACT NOW

BeMedTech Award

One award will be distributed during the RBSLM Annual Meeting.

Requirements:

Application procedure:

The beMedTech Award recognizes outstanding scientific contributions that demonstrate the clinical and economic value of In Vitro Diagnostic (IVD) tests within the healthcare system. The primary goal of the award is to highlight how IVD tests contribute to healthcare sustainability, optimized care pathways, and reduced overall healthcare expenditure (e.g., preventing unnecessary hospitalizations or redundant procedures).

  1. Mandatory Eligibility Criteria

    Abstracts must meet all the following conditions to be considered for evaluation:

    • Generic Test Focus: The abstract must focus on a generic IVD analyte, marker, or technology. Submissions mentioning commercial brand names, trademarked products, or proprietary manufacturer platforms will be disqualified.
    • CE-IVD tests: The subject must be a standardized, commercially available IVD test.
    • Integration into a care pathway/Economic impact: The abstract must evaluate the clinical or economic impact of a generic IVD test (can include also multiplex assays) or its integration into a care pathway.
    • Ethics & Compliance: The study must comply with applicable ethical guidelines and Belgian/European regulations for medical diagnostic research.
  2. Weighted Selection Criteria

    Eligible abstracts will be evaluated across four core categories:

    A. Health-Economic Value & Efficiency

    • Cost Avoidance & Impact: Demonstrates a measurable potential to reduce healthcare costs (e.g., preventing unnecessary hospital admissions, shortening length of stay, …).
    • Resource Optimization: Demonstrates efficient use of diagnostic resources that contributes to the long-term financial sustainability of the healthcare system.

    B. Care Pathway

    • Right Care, Right Time, Right Place: Evaluates whether the test enables timely decision-making at the appropriate level of care (e.g., primary care triage, rapid emergency decision-making, specialized care).

    C. Reimbursement relevance and patient value

    • Reimbursement readiness & dossier Value: Relevance of the clinical and economic data in providing the necessary evidence base required by decision bodies (e.g., Article 24, 24bis, 33, or specific convention pathways) to establish or update the nomenclature.
    • Or democratizing Access: Demonstrates how public reimbursement would ensure equitable access across all socio-economic groups, removing out-of-pocket barriers.

    D. Scientific Rigor

    • Clinical Validity & Utility: Provides solid scientific evidence linking test results to improved clinical outcomes and decision-making, integrating current scientific literature and clinical expertise.

Application Deadline: September 24, 2026 - 23:59

The selected abstracts and winners will be notified around October 15, 2026

SUBMIT YOUR ABSTRACT NOW